Literature DB >> 14747950

Peripapillary atrophy in the unilateral exfoliation syndrome.

Päivi Puska1, Mika Harju, Ron Liebkind.   

Abstract

PURPOSE: To compare the areas of peripapillary atrophy between fellow eyes in patients with unilateral exfoliation syndrome.
METHODS: Topographic measurements for peripapillary atrophy and the optic nerve head with confocal scanning laser ophthalmoscopy, using the Heidelberg Retina Tomograph were performed on 45 nonglaucomatous patients with unilateral exfoliation syndrome. The area of peripapillary atrophy was divided into an alpha and a beta zone. The areas of alpha and beta peripapillary atrophy and their angular extents around the disc were measured. The frequency distributions of the alpha and beta areas and their largest radial extents at different positions around the disc were calculated.
RESULTS: An alpha area was detected in 84% of the exfoliative and 89% of the nonexfoliative fellow eyes, and a beta area in 31% and 42% of eyes, respectively. The exfoliative and the fellow nonexfoliative eyes did not differ in the sizes of the alpha (0.43+/-0.46 vs 0.33+/-0.18 mm(2), P=0.68) and beta (0.14+/-0.30 vs 0.17+/-0.34 mm(2), P=0.96) areas of peripapillary atrophy. The angular extents, the locations of the largest radial extent, and the frequency distributions of the alpha and beta peripapillary atrophy areas were similar in fellow eyes.
CONCLUSION: Exfoliation syndrome itself is not a risk factor for peripapillary atrophy.

Entities:  

Mesh:

Year:  2004        PMID: 14747950     DOI: 10.1007/s00417-003-0843-1

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  35 in total

1.  Unilateral or asymmetric pseudoexfoliation syndrome? An ultrastructural study.

Authors:  T Hammer; U Schlötzer-Schrehardt; G O Naumann
Journal:  Arch Ophthalmol       Date:  2001-07

2.  Fluorescein angiography of the optic disc and the peripapillary area in chronic glaucoma.

Authors:  C Raitta; T Sarmela
Journal:  Acta Ophthalmol (Copenh)       Date:  1970

3.  Early signs of the glaucomatous disc.

Authors:  J Primrose
Journal:  Br J Ophthalmol       Date:  1971-12       Impact factor: 4.638

4.  Factors contributing to the progression of visual field damage in eyes with normal-tension glaucoma.

Authors:  M Araie; M Sekine; Y Suzuki; N Koseki
Journal:  Ophthalmology       Date:  1994-08       Impact factor: 12.079

5.  Reproducibility of the optic nerve head topography with a new laser tomographic scanning device.

Authors:  K Rohrschneider; R O Burk; F E Kruse; H E Völcker
Journal:  Ophthalmology       Date:  1994-06       Impact factor: 12.079

6.  Blood supply of the optic nerve head and its role in optic atrophy, glaucoma, and oedema of the optic disc.

Authors:  S S Hayreh
Journal:  Br J Ophthalmol       Date:  1969-11       Impact factor: 4.638

7.  Increasing peripapillary atrophy is associated with progressive glaucoma.

Authors:  H Uchida; S Ugurlu; J Caprioli
Journal:  Ophthalmology       Date:  1998-08       Impact factor: 12.079

8.  Correlation of the peripapillary atrophy area with optic disc cupping and disc hemorrhage.

Authors:  T Hayakawa; K Sugiyama; G Tomita; K Kawase; E Onda; H Shinohara; A Tsuji; Y Kitazawa
Journal:  J Glaucoma       Date:  1998-10       Impact factor: 2.503

9.  The relationship between the fluoroangiographic aspect of the optic disk and the visual field in patients with the exfoliation syndrome with and without intraocular hypertension. Part I: Bilateral cases.

Authors:  A Cambiaggi; A Marras
Journal:  Acta Ophthalmol Suppl       Date:  1988

10.  Acquired peripapillary changes and progression in glaucoma.

Authors:  E J Rockwood; D R Anderson
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1988       Impact factor: 3.117

View more
  1 in total

1.  Scanning laser ophthalmoscopic parameters of eyes with exfoliation syndrome.

Authors:  Ali Bulent Cankaya; Emrullah Beyazyildiz
Journal:  Jpn J Ophthalmol       Date:  2010-08-11       Impact factor: 2.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.